Martek Biosciences Corp.

Martek Bioscience (MATK) announced in September that made it a multiple license and supply deal with an international food companies, Hero, Grupo Ricap, and Hochdorf Nutricare. Martek will supply all of companies' ARA and DHA for infant formula and children's food and milk, specially designed for a child's early life.

The deal allows Martek to continue its international expansion into Mexico, Europe, and China. Martek's proprietary DHA and ARA blend is used in approximately 95% of infant formulas sold in the U.S.

On Sep 4 Martek announced third-quarter earnings that included earnings per share of 28 cents. This market the fourth surprise in the past 4 quarters, as analysts were only expecting 24 cents. Revenues rose 14% year-over-year to $88.4 million.

Martek also raised full-year guidance during the announcement. The company expects earnings per share to be between $1.06 and $1.09, 65% higher that 2007.

The company was featured earlier this year as a Zacks Rank Buy.

Read the March 11th analysis.

Last Week's Aggressive Growth Zacks Rank Buy Stocks

Ulta Salon, Cosmetics & Fragrance, Inc. (ULTA - Snapshot Report) continues to aggressively expand its footprint across the U.S. The beauty retailer and salon is also coming of off its third earnings surprise and is priced at a reasonable PEG ratio of 0.58. Read Full Article.

Perrigo Company (PRGO - Analyst Report) has acquired 2 more laboratories this quarter in a focused effort on growth in existing markets. The company is also coming off of a record quarterly earnings report. Read Full Article.

Revlon, Inc. (REV - Snapshot Report) is paying down debt and focusing on its core business. The company has also seen an increase in sales despite a tough economy. Read Full Article.

Zhongpin Inc. (HOGS - Snapshot Report) just raised earnings guidance and it trading at a bargain PEG ratio of just 0.26. The company hopes to build off of a second quarter as one of its newest plants is already contributing to revenue. Read Full Article.

Read the full analyst report on MATK